An economic evaluation of nivolumab for the treatment of squamous and non-squamous NSCLC in the Swedish setting
The cost-effectiveness of nivolumab versus docetaxel in patients with previously treated non-small cell lung cancer (NSCLC) was estimated in a cohort-based, partitioned survival model with three health states (progression-free, progressed disease, and death) and a time horizon of 15 years. The base-...
Saved in:
Main Authors: | Caitlin Smare (Author), Meena Venkatachalam (Author), Emma Medin (Author), Marcus Hultberg (Author), John R Penrod (Author), Nadine Hertel (Author), Michael Lees (Author), Christoffer Holmberg (Author) |
---|---|
Format: | Book |
Published: |
University of Oslo,
2019-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
by: Marcos Oro-Ayude, et al.
Published: (2020) -
The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions
by: David Campbell, et al.
Published: (2018) -
Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions
by: Mark Edmondson-Jones, et al.
Published: (2022) -
Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022) -
The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions
by: Mark Edmondson-Jones, et al.
Published: (2021)